INTERCEPT Pathogen-Reduced PlasmaReduce Patient Risk of Transfusion Transmitted Infection
What is INTERCEPT Plasma?
The INTERCEPT Blood System for Plasma, pathogen reduction system, provides broad-spectrum reduction of pathogens and leukocytes, reducing the risks of transfusion-transmitted infection (TTI) from known and emerging pathogens, as well as transfusion-associated graft-versus-host disease (TA GvHD). INTERCEPT-treated plasma has a proven track record of safety and has demonstrated equivalent therapeutic efficacy to conventional plasma in clinical trials. Furthermore, the INTERCEPT treatment for plasma and platelets can occur on the same Illuminator platform for optimal efficiency.
Broad spectrum of pathogens inactivated by the INTERCEPT Blood System for Plasma1
DHBV (model for HBV)
BVDV (Model for HCV)
1. INTERCEPT Blood System for Plasma [Package Insert]. Concord, CA: Cerus Corporation; May 1, 2020.